TY - JOUR T1 - Buflomedil reduced cardiovascular events in peripheral arterial disease JF - Evidence Based Medicine JO - Evid Based Med SP - 141 LP - 141 DO - 10.1136/ebm.13.5.141 VL - 13 IS - 5 A2 - , Y1 - 2008/10/01 UR - http://ebm.bmj.com/content/13/5/141.abstract N2 - A LeizoroviczDr A Leizorovicz, Service de Pharmacologie Clinique, Lyon, France; al@upcl.univ-lyon1.frDesign:randomised placebo controlled trial (Limbs International Medicinal Buflomedil [LIMB]).Allocation:concealed.*Blinding:blinded (patients and outcome assessors).*Setting:123 centres in the Czech Republic, France, Hungary, and Russia.Patients:2078 patients who were 40–90 years of age (median age 61 y, 80% men) and had documented peripheral arterial obstructive disease (PAD) and an ankle-brachial index at rest >0.30 and ⩽0.80. Exclusion criteria were ischaemic rest pain, ulceration or gangrene, iliac or common femoral artery stenosis or occlusion, arterial occlusion of embolic origin, Buerger disease or any non-atherosclerotic arterial disease of … ER -